Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis

Emily J Meyer, Venkatesan Thiruvenkatarajan and David Jesudason
Med J Aust 2021; 214 (2): . || doi: 10.5694/mja2.50899
Published online: 1 February 2021

To the Editor: We would like to highlight some points arising from the discussion by Hamblin and colleagues regarding euglycaemic diabetic ketoacidosis associated with sodium–glucose cotransporter type 2 (SGLT2) inhibitors.1

  • Emily J Meyer1,2
  • Venkatesan Thiruvenkatarajan1,2
  • David Jesudason1,2

  • 1 The Queen Elizabeth Hospital, Adelaide, SA
  • 2 University of Adelaide, Adelaide, SA


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.